Back to top
more

CytoDyn Inc. (CYDY)

(Delayed Data from OTC)

$2.91 USD

2.91
1,573,639

+0.22 (8.18%)

Updated May 7, 2021 03:59 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy25.41%
2Buy19.02%
3Hold10.72%
4Sell6.46%
5Strong Sell3.06%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 17% (210 out of 254)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Zacks News

CytoDyn (CYDY) Files New Protocol With FDA for COVID-19 Study

CytoDyn (CYDY) submits a new protocol with the regulatory body in the United States to study a higher dose of leronlimab for severely-infected COVID-19 patients.

CytoDyn (CYDY) Completes Enrollment in Phase III COVID-19 Study

CytoDyn (CYDY) completes full enrollment for its phase III registrational study of Vyrologix for the treatment of patients with severe-to-critical COVID-19.

CytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab

CytoDyn (CYDY) enrolls first patient in the phase II study evaluating leronlimab for the treatment of nonalcoholic steatohepatitis.

CytoDyn Reports Top-Line Data From Phase II Coronavirus Study

CytoDyn (CYDY) announces top-line results from a phase II study evaluating leronlimab in COVID-19 patients with mild-to-moderate symptoms.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Offing?

CytoDyn's progress on its lead candidate, leronlimab, will be in focus when it reports Q4 results.

CytoDyn Signs MOU With NIH of Mexico for Coronavirus Study

CytoDyn's (CYDY) shares rise more than 20% as it inks an MOU with NIH of Mexico to conduct a COVID-19 study on leronlimab.

Ritujay Ghosh headshot

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?

On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.

Zacks.com headshot

Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners

Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.

CytoDyn's Leronlimab Progressing Well in Coronavirus Program

CytoDyn (CYDY) treats first patient in a phase IIb/III study evaluating leronlimab in severe and critically ill COVID-19 patients. A phase II study on leronlimab shows encouraging results in mild-to-moderate COVID-19 patients.

Calithera (CALA) Soars: Stock Adds 9.4% in Session

Calithera (CALA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis

The Zacks Analyst Blog Highlights: Champions Oncology, CytoDyn, Infinity Pharmaceuticals, Nektar Therapeutics and Zoetis

5 Best Biotech Stocks to Buy In October

Successful drug trials at several biopharmas and FDA approvals make biotech companies a strong investment choice in October

New Strong Sell Stocks for February 23rd

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:

Can CytoDyn (CYDY) Run Higher on Strong Earnings Estimate Revisions?

CytoDyn (CYDY) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.